Recent advances in chemotherapy for advanced gastric cancer in Japan

Surgery Today

Volumn 40, Issue 4, 2010, Pages 295-300

  Fujii, Masashi ^a   Kochi, Mitsugu ^a   Takayama, Tadatoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Gastric cancer; Standard chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; METHOTREXATE; MITOMYCIN C; PACLITAXEL; UFT;

ADVANCED CANCER; ANEMIA; ANOREXIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GASTRECTOMY; GRANULOCYTOPENIA; HUMAN; JAPAN; LETHARGY; LEUKOPENIA; MALAISE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PROTEINURIA; RECOMMENDED DRUG DOSE; REVIEW; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; STOMACH TUMOR;

HUMANS; STOMACH NEOPLASMS;

EID: 77953943945     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-009-4148-9     Document Type: Review

References (25)

1. Tsukuma H, editor. Progress report of the Research Group for Population-based Cancer Registration in Japan. 2002.
2. Kitagawa T, Tsukuma H, Tominaga S, editors. Prediction of cancer incidence in Japan. Cancer Statistics 1999. Tokyo: Shinohara Shuppan; 1999.
3. Comis S. Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rev 1974;1:221-38.
4. Cocconi G, DeLisi V, DiBlasio B: Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 1982;66:1263-6.
5. The Gastrointestinal Tumor Study Group. Phase II/III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 1979;63:1871-6.
6. Moertel CG, Lavin PT. Phase II/III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 1979;63:1863-9.
7. Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Heinicke A, et al. Chemotherapy of gastric cancer. Cancer Treat Rev 1988;15:257-77.
8. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72:37-41.
9. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71: 587-91.
10. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 1999;80:269-72.
11. Moiseyenko VM, Ajani JA, Tjulandin SA, Majlis A, Constenia M, Boni C, et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). In: ASCO 2005 (abstract 4002).
12. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21:54-9.
13. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
14. Boku N, Ohtsu A, Shimada Y, Sirao K, Seki S, Saito H, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-23.
15. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89(12):2207-12.
16. Komatsu Y, Yuki S, Tateyama M, Kudo M, Asaka M. Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen (in Japanese with English abstract). Gan to Kagaku Ryoho (Jpn J Cancer Chemother) 2006;33 suppl 1:131-4.
17. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, et al. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006;12:3042-7.
18. Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, et al. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 2006;94:1803-8.
19. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008;9(3):215-21.
20. Imamura H, IIishi H, Tsuburaya A, Hatake K, Imamoto H, Esaki T, et al. Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). In: ASCO GI 2008; Abstract #5.
21. Fujii M. Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). Int J Clin Oncol 2008;13:201-5.
22. Nakayama N, Koizumi W, Sasaki T, Higuchi K, Tanabe S, Nishimura K, et al. A multicenter, phase I dose-escalating study of docetaxel, cisplatin and S-1 for advanced gastric cancer (KDOG0601). Oncology 2008;75(1-2):1-7.
23. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357: 1810-20.
24. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
25. Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, et al. Randomized controlled study of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007;94:1468-76.